(E)-2-氰基-3-(4-羟基-3,5-二异丙苯基)-N-(3-苯基丙基)丙烯酰胺
(E)-2-氰基-3-(4-羟基-3,5-二异丙苯基)-N-(3-苯基丙基)丙烯酰胺
(E)-2-氰基-3-(4-羟基-3,5-二异丙苯基)-N-(3-苯基丙基)丙烯酰胺 性质
| 熔点 | 126 °C |
|---|---|
| 沸点 | 590.6±50.0 °C(Predicted) |
| 密度 | 1.100±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | 溶于二甲基亚砜。 |
| 酸度系数(pKa) | 10.30±0.36(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| 稳定性 | 自购买之日起 1 年内保持稳定。 DMSO 中的溶液可在 -20° 下保存长达 3 个月。 |
| CAS 数据库 | 168835-82-3 |
(E)-2-氰基-3-(4-羟基-3,5-二异丙苯基)-N-(3-苯基丙基)丙烯酰胺 用途与合成方法
| Target | Value |
|
KDR
() |
SU1498 stimulates accumulation of phosphorylated ERKs in human umbilical vein endothelial cells and in human aortic endothelial cells in a manner that is dependent on the functioning of the upstream components of the MAPK pathway, B-Raf, and MEK kinases. The enhanced accumulation of phospho-ERKs is observed only in cells that have been stimulated with sphingosine 1-phosphate or protein growth factors; SU1498 by itself is ineffective. SU1498 blocks signal transduction from VEGFR2 in MS1 VEGF cells.In the presence of SU1498, levels of Ets-1 are decreased, suggesting that VEGF-VEGFR-2 interactions contributed to baseline levels of Ets-1 expression, and interruption of this autocrine interaction with SU1498 led to decreased expression of Ets-1. SU1498 treatment significantly impacts U87 cell proliferation and apoptosis. SU1498 induces a marked increase in lipids and a decrease in glycerophosphocholine. Accordingly, accumulation of lipid droplets is seen in the cytoplasm of SU1498-treated U87 cells.
(E)-2-氰基-3-(4-羟基-3,5-二异丙苯基)-N-(3-苯基丙基)丙烯酰胺 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | U0103 | SU 1498 | 168835-82-3 | 5mg | 220 |
| 2024-04-30 | S6535 | (E)-2-氰基-3-(4-羟基-3,5-二异丙苯基)-N-(3-苯基丙基)丙烯酰胺 | 168835-82-3 | 5mg | 794.93 |
